AngioDynamics (ANGO)
(Delayed Data from NSDQ)
$6.25 USD
-0.01 (-0.16%)
Updated Apr 22, 2024 11:54 AM ET
After-Market: $6.26 +0.01 (0.16%) 7:58 PM ET
4-Sell of 5 4
C Value D Growth D Momentum D VGM
AngioDynamics (ANGO) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$13.25 | $17.00 | $10.00 | 111.66% |
Price Target
Based on short-term price targets offered by four analysts, the average price target for AngioDynamics comes to $13.25. The forecasts range from a low of $10.00 to a high of $17.00. The average price target represents an increase of 111.66% from the last closing price of $6.26.
Analyst Price Targets (4 )
Broker Rating
AngioDynamics currently has an average brokerage recommendation (ABR) of 1.25 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by four brokerage firms. The current ABR compares to an ABR of 1.75 a month ago based on four recommendations.
Of the four recommendations deriving the current ABR, three are Strong Buy and one is Buy. Strong Buy and Buy respectively account for 75% and 25% of all recommendations. A month ago, Strong Buy made up 50%, while Buy represented 25%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 3 | 3 | 2 | 2 | 2 |
Buy | 1 | 1 | 1 | 1 | 1 |
Hold | 0 | 0 | 1 | 1 | 1 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.25 | 1.25 | 1.75 | 1.75 | 1.75 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
1/9/2024 | Raymond James | Jayson T Bedford | Moderate Buy | Moderate Buy |
1/8/2024 | H.C. Wainwright & Co. | Yi Chen | Strong Buy | Strong Buy |
10/5/2023 | Canaccord Genuity | William J Plovanic | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.25 |
ABR (Last week) | 1.25 |
# of Recs in ABR | 4 |
Average Target Price | $13.25 |
LT Growth Rate | NA |
Industry | Medical - Instruments |
Industry Rank by ABR | 98 of 252 |
Current Quarter EPS Est: | -0.17 |